Treatment of Photoaging

New England Journal of Medicine

Volumn 350, Issue 15, 2004, Pages 1526-1534

  Stern, Robert S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BETA CAROTENE; BOTULINUM TOXIN; BOTULINUM TOXIN A; COLLAGEN; COLLAGEN IMPLANT; COPPER; DICLOFENAC; EMOLLIENT AGENT; FILLER; FLUOROURACIL; GLYCOLIC ACID; HYALURONIC ACID; HYDROXYACID; LACTIC ACID; LIQUID NITROGEN; RETINAL; RETINOIC ACID; RETINOID; RETINOL; SUNSCREEN; TAZAROTENE; DERMATOLOGICAL AGENT;

ACTINIC KERATOSIS; AGING; ANGIOMA; ARGON LASER; ARTICLE; CANCER RISK; CATTLE; CLINICAL TRIAL; CREAM; CRYOSURGERY; CUTANEOUS PARAMETERS; DISEASE COURSE; DRUG COST; DRUG HYPERSENSITIVITY; ERBIUM YAG LASER; EYELID RECONSTRUCTION; FACE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERPIGMENTATION; LASER SURGERY; LENTIGO; LOTION; MUSCLE HYPERTONIA; NEODYMIUM LASER; NONHUMAN; PAIN; PHOTOAGING; PHOTODYNAMIC THERAPY; PIGMENT DISORDER; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REJUVENATION; RHYTIDOPLASTY; RISK FACTOR; RISK REDUCTION; SKIN ABRASION; SKIN BRUISING; SKIN CANCER; SKIN CARCINOGENESIS; SKIN DISEASE; SKIN IRRITATION; SKIN MANIFESTATION; SKIN SURGERY; SMOKING; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TELANGIECTASIA; TREATMENT INDICATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VAPOR; WRINKLE; ESTHETIC SURGERY; FEMALE; HISTOLOGY; LASER; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; REVIEW; SKIN;

BOTULINUM TOXINS; COSMETIC TECHNIQUES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LASERS; LENTIGO; MIDDLE AGED; PRACTICE GUIDELINES; SKIN; SKIN AGING; SUNSCREENING AGENTS; TELANGIECTASIS;

EID: 2142698024     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp023168     Document Type: Article

References (60)

1. Lévêque J-L. Quantitative assessment of skin aging. Clin Geriatr Med 2001;17:673-89.
2. Holman CDJ, Evans PR, Lumsden GJ, Armstrong BK. The determinants of actinic skin damage: problems of confounding among environmental and constitutional variables. Am J Epidemiol 1984;120:414-22.
3. Holman CDJ, Armstrong BK, Evans PR, et al. Relationship of solar keratosis and history of skin cancer to objective measures of actinic skin damage. Br J Dermatol 1984; 110:129-38.
4. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142:1154-9.
5. Brooke RC, Newbold SA, Telfer NR, Griffiths CEM. Discordance between facial wrinkling and the presence of basal cell carcinoma. Arch Dermatol 2001;137:751-4.
6. Foote JA, Harris RB, Giuliano AR, et al. Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. Int J Cancer 2001;95:7-11.
7. Malvy J-MD, Guinor C, Preziosi P, et al. Epidemiologic determinants of skin photoaging: baseline data of the SU.VI.MAX. cohort. J Am Acad Dermatol 2000;42:47-55.
8. Kennedy C, Bastiaens MT, Bajdik CD, Willemze K, Westendorp RGJ, Bouwes Bavinck JN. Effect of smoking and sun on the aging skin. J Invest Dermatol 2003;120: 548-54.
9. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327: 1649-62.
10. de Gruijl FR, Sterenborg HJ, Forbes PD, et al. Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res 1993;53:53-60.
11. Kligman LH, Akin FJ, Kligman AM. The contributions of UVA and UVB to connective tissue damage in hairless mice. J Invest Dermatol 1985;84:272-6.
12. American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2002 Statistics. New York: ASAPS Communications, 2003. (Accessed March 15, 2004, at http://www.surgery.org/press/statistics-2002.asp).
13. Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003;139: 451-5.
14. Kligman LH, Akin FJ, Kligman AM. Prevention of ultraviolet damage to the dermis of hairless mice by sunscreens. J Invest Dermatol 1982;78:181-9.
15. Idem. Sunscreens promote repair of ultraviolet radiation-induced dermal damage. J Invest Dermatol 1983;81:98-102.
16. Boyd AS, Naylor M, Cameron GS, Pearse AD, Gaskell SA, Neldner KH. The effects of chronic sunscreen use on the histologic changes of dermatoheliosis. J Am Acad Dermatol 1995;33:941-6.
17. Stern RS, Weinstein MC, Baker SG. Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch Dermatol 1986;122:537-45.
18. Neale R, Williams G, Green A. Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 2002;138: 1319-25.
19. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51.
20. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354: 723-9. [Erratum, Lancet 1999;354:1038.]
21. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354: 723-9. [Erratum, Lancet 1999;354:1038.]
22. Foley P, Nixon R, Marks R, Frowen K, Thompson S. The frequency of reactions to sunscreens: results of a longitudinal population-based study on the regular use of sunscreens in Australia. Br J Dermatol 1993;128: 512-8.
23. Autier P, Dore JF, Negrier S, et al. Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Insr 1999;91:1304-9.
24. Huncharek M, Kupelnick B. Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case-control studies. Am J Public Health 2002;92:1173-7.
25. Center for Food Safety and Applied Nutrition. AHAs and UV sensitivity: results of new FDA-sponsored studies. Office of Cosmetics and Colors fact sheet. Rockville, Md.: Food and Drug Administration, March 7, 2000.
26. Stiller MJ, Bartolone J, Stern RS, et al. Topical 8% glycolic acid and 8% L-lactic acid creams for the treatment of photodamaged skin: a double-blind vehicle-controlled clinical trial. Arch Dermatol 1996;132:631-6.
27. Thibault PK, Wlodarczyk J, Wenck A. A double-blind randomized clinical trial on the effectiveness of a daily glycolic acid 5% formulation in the treatment of photoaging. Dermatol Surg 1998;24:573-8.
28. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA 1988; 259:527-32. [Errata, JAMA 1988;259:3274, 260:926.]
29. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA 1988; 259:527-32. [Errata, JAMA 1988;259:3274, 260:926.]
30. Griffiths CEM, Russman AN, Majmudar G, Singer RS, Hamilton TA, Voorhees JJ. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med 1993;329:530-5.
31. Renova (tretinoin cream) 0.05%: prescribing information, Skillman, N.J.: Ortho Dermatological, 1998 (package insert).
32. Renova (tretinoin cream) 0.02%: prescribing information. Skillman, N.J.: Ortho Dermatological, 2000 (package insert).
33. Avage (tazarotene) cream, 0.1%: prescribing information. Irvine, Calif.; Allergan, 2002 (package insert).
34. Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001;137:1597-604.
35. Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999;41:927-30.
36. Frosr C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000;115:273-7.
37. Drake LA, Ceilley RJ, Cornelison RL, et al. Guidelines of care for actinic keratoses: committee on guidelines of care. J Am Acad Dermatol 1995;32:95-8.
38. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41:414-8.
39. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997;23:191-6.
40. Food and Drug Administration. Proceedings of the Dermatologic and Ophthalmic Drugs Advisory Committee. Gaithersburg, Md.: Center for Drug Evaluation and Research, November 5, 1999.
41. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-3.
42. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502.
43. 2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999;25:729-32.
44. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996;35:569-72.
45. Botox cosmetic purified neurotoxin complex (Allergan). In: Physicians' desk reference electronic library. Montvale, N.J.: Thompson PDR, 2003:1-15 (computer disk).
46. Warning letter to Allergan, Inc. Rockville, Md.: Food and Drug Administration, June 23, 2003. (Accessed March 15, 2004, at http://www.fda.gov/foi/warning_letters/g4093d.htm.)
47. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.
48. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003;29:7-13.
49. Klein AW. Skin filling: collagen and other injectables of the skin. Dermatol Clin 2001;19:491-508.
50. FDA approves new product for facial wrinkles. FDA talk paper T03-85. Rockville, Md.: Food and Drug Administration, December 12, 2003.
51. Stern RS, Dover JS, Levin JA, Arndt KA. Laser therapy versus cryotherapy of lentigines: a comparative trial. J Am Acad Dermatol 1994;30:985-7.
52. Hernandez-Perez E, Ibiett EV. Gross and microscopic findings in patients undergoing microdermabrasion for facial rejuvenation. Dermatol Surg 2001;27:637-40.
53. Maheux R, Naud P, Rioux M, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170:642-9.
54. Dunn LB, Damesyn M, Moore AA, Reuben DB, Greendale GA. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I). Arch Dermatol 1997; 133:339-42.
55. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
56. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for photoaging/photodamage. J Am Acad Dermatol 1996; 35:462-4.
57. Guidelines of care for cryosurgery. J Am Acad Dermatol 1994;31:648-53.
58. Guidelines of care for soft tissue augmentation: collagen implants. J Am Acad Dermatol 1996;34:698-702.
59. Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for chemical peeling. J Am Acad Dermatol 1995;33:497-503.
60. Guidelines of care for dermabrasion. J Am Acad Dermatol 1994;31:654-7.